Treatment Resistant Depression Group-Institute of Psychiatry from the Federal University of Rio de Janeiro (IPUB-UFRJ), Rio de Janeiro, Brazil.
PLoS One. 2024 Oct 15;19(10):e0306227. doi: 10.1371/journal.pone.0306227. eCollection 2024.
Major Depressive Disorder (MDD) is a global health issue, and a significant portion of individuals with MDD experience Treatment-Resistant Depression (TRD), characterized by the lack of response to adequately trialed antidepressant medication and therapy. This systematic review aims to investigate the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) as an intervention for individuals with TRD.
We will conduct a thorough search for publications of randomized clinical trials and quasi-experimental studies in MEDLINE, Embase, PsycINFO, Web of Science databases, and ClinicalTrials.gov. Furthermore, reference lists of included studies will be manually screened for additional relevant articles, with no restrictions on language or publication date. The search will be conducted from the inception of the databases until June 2024. Our PICO-guided research questions are: (1) In adults with Treatment-Resistant Depression, is MBCT more effective than standard care or other active treatments in reducing depressive symptoms? (2) In adults with Treatment-Resistant Depression, does MBCT demonstrate a comparable safety profile to standard care or other active treatments? The quality of the included studies will be assessed independently using the Cochrane Risk of Bias Tool (RoB 2). This study seeks to evaluate the effectiveness and tolerability of Mindfulness-Based Cognitive Therapy as an intervention for Treatment-Resistant Depression, and will employ the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to appraise the confidence in the evidence.
Prospero registration ID: CRD42023411978. Registered on April 07, 2023.
重度抑郁症（MDD）是一个全球性的健康问题，相当一部分 MDD 患者经历了治疗抵抗性抑郁症（TRD），其特征是对充分试验的抗抑郁药物和治疗没有反应。本系统评价旨在研究正念认知疗法（MBCT）作为治疗 TRD 患者的干预措施的有效性。
我们将在 MEDLINE、Embase、PsycINFO、Web of Science 数据库和 ClinicalTrials.gov 中全面搜索随机临床试验和准实验研究的出版物。此外，还将手动筛选纳入研究的参考文献列表，以获取其他相关文章，对语言和出版日期没有限制。搜索将从数据库建立开始进行，直到 2024 年 6 月。我们的 PICO 指导的研究问题是：（1）在治疗抵抗性抑郁症的成年人中，MBCT 在减轻抑郁症状方面是否比标准护理或其他积极治疗更有效？（2）在治疗抵抗性抑郁症的成年人中，MBCT 是否表现出与标准护理或其他积极治疗相当的安全性？纳入研究的质量将使用 Cochrane 风险偏倚工具（RoB 2）独立评估。本研究旨在评估正念认知疗法作为治疗抵抗性抑郁症的干预措施的有效性和耐受性，并将采用推荐评估、制定与评价（GRADE）方法评估证据的可信度。
PROSPERO 注册号：CRD42023411978。注册于 2023 年 4 月 7 日。
